CA2882132C - Kappa opioid ligands - Google Patents
Kappa opioid ligands Download PDFInfo
- Publication number
- CA2882132C CA2882132C CA2882132A CA2882132A CA2882132C CA 2882132 C CA2882132 C CA 2882132C CA 2882132 A CA2882132 A CA 2882132A CA 2882132 A CA2882132 A CA 2882132A CA 2882132 C CA2882132 C CA 2882132C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- rac
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683861P | 2012-08-16 | 2012-08-16 | |
| US61/683,861 | 2012-08-16 | ||
| PCT/US2013/055313 WO2014028829A1 (en) | 2012-08-16 | 2013-08-16 | Novel kappa opioid ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2882132A1 CA2882132A1 (en) | 2014-02-20 |
| CA2882132C true CA2882132C (en) | 2021-07-06 |
Family
ID=50101521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2882132A Active CA2882132C (en) | 2012-08-16 | 2013-08-16 | Kappa opioid ligands |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9682966B2 (enExample) |
| EP (2) | EP3584246A1 (enExample) |
| JP (3) | JP6254163B2 (enExample) |
| AU (3) | AU2013302497A1 (enExample) |
| CA (1) | CA2882132C (enExample) |
| DK (1) | DK2884978T3 (enExample) |
| ES (1) | ES2750640T3 (enExample) |
| WO (1) | WO2014028829A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2750640T3 (es) | 2012-08-16 | 2020-03-26 | Scripps Research Inst | Ligandos opioides kappa novedosos |
| US10982041B2 (en) * | 2016-02-25 | 2021-04-20 | Swancor Advanced Materials Co., Ltd. | Epoxy resin oligomer |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| DK3596069T3 (da) * | 2017-03-17 | 2022-08-01 | Scripps Research Inst | Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| WO2019000238A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019113419A1 (en) * | 2017-12-08 | 2019-06-13 | The Rockefeller University | Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| KR20250141271A (ko) * | 2023-02-17 | 2025-09-26 | 더 스크립스 리서치 인스티튜트 | 카파-오피오이드 수용체 길항제로서 작용하는 퀴놀린 유도체 |
| WO2024216046A1 (en) | 2023-04-13 | 2024-10-17 | Neumora Therapeutics, Inc. | Methods of treating anhedonia |
| WO2024216061A1 (en) | 2023-04-13 | 2024-10-17 | Neumora Therapeutics, Inc. | Methods of treating depression and anhedonia |
| EP4762046A1 (en) * | 2023-08-18 | 2026-06-24 | The Scripps Research Institute | Kappa-opioid receptor antagonists |
| TW202515866A (zh) * | 2023-09-05 | 2025-04-16 | 大陸商西藏海思科製藥有限公司 | Kor拮抗劑及其在醫藥上的應用 |
| WO2025250535A1 (en) | 2024-05-28 | 2025-12-04 | Neumora Therapeutics, Inc. | Methods of treating depression and anhedonia |
| WO2025257758A1 (en) | 2024-06-11 | 2025-12-18 | Assia Chemical Industries Ltd. | Solid state forms of navacaprant |
| WO2026103730A1 (zh) * | 2024-11-15 | 2026-05-21 | 江苏恩华药业股份有限公司 | 一种具有kappa受体拮抗活性的吡啶并芳基的双氮杂环衍生物及其组合物和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4014171A1 (de) * | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
| JP2525552B2 (ja) | 1992-01-23 | 1996-08-21 | 東レ株式会社 | モルヒナン誘導体および医薬用途 |
| AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| ES2325140T3 (es) * | 1998-04-20 | 2009-08-26 | ABBOTT GMBH & CO. KG | Amidas sustituidas con heterociclos como inhibidores de la calpaina. |
| US6284769B1 (en) | 1999-12-03 | 2001-09-04 | The Board Of Trustees Of The University Of Illinois | Nonpeptide kappa opioid receptor antagonists |
| US7381721B2 (en) * | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| AU2004274403A1 (en) * | 2003-09-03 | 2005-03-31 | Aventis Pharmaceuticals Inc. | 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| WO2005028438A1 (ja) * | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
| ES2374629T3 (es) | 2004-03-17 | 2012-02-20 | Pfizer Products Incorporated | Nuevos derivados de bencil(iden)-lactama. |
| DE602005023763D1 (de) * | 2004-11-04 | 2010-11-04 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine |
| GB0510204D0 (en) * | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2007045462A2 (de) * | 2005-10-19 | 2007-04-26 | Grünenthal GmbH | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln |
| WO2007050348A2 (en) * | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Potassium channel inhibitors |
| CN101583593A (zh) | 2006-11-13 | 2009-11-18 | 辉瑞产品公司 | 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途 |
| CA2708741A1 (en) | 2007-12-10 | 2009-06-18 | Glaxo Group Limited | Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
| WO2011025799A1 (en) * | 2009-08-26 | 2011-03-03 | Glaxo Group Limited | Cathepsin c inhibitors |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| ES2552932T3 (es) * | 2009-12-29 | 2015-12-03 | Suven Life Sciences Limited | Ligandos del receptor nicotínico neuronal de la acetilcolina alfa4beta2 |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
| WO2012123449A1 (en) * | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| ES2750640T3 (es) | 2012-08-16 | 2020-03-26 | Scripps Research Inst | Ligandos opioides kappa novedosos |
-
2013
- 2013-08-16 ES ES13829428T patent/ES2750640T3/es active Active
- 2013-08-16 CA CA2882132A patent/CA2882132C/en active Active
- 2013-08-16 DK DK13829428.5T patent/DK2884978T3/da active
- 2013-08-16 JP JP2015527656A patent/JP6254163B2/ja active Active
- 2013-08-16 EP EP19186416.4A patent/EP3584246A1/en not_active Withdrawn
- 2013-08-16 EP EP13829428.5A patent/EP2884978B1/en active Active
- 2013-08-16 AU AU2013302497A patent/AU2013302497A1/en not_active Abandoned
- 2013-08-16 US US14/421,932 patent/US9682966B2/en active Active
- 2013-08-16 WO PCT/US2013/055313 patent/WO2014028829A1/en not_active Ceased
-
2017
- 2017-05-15 US US15/595,436 patent/US10118915B2/en active Active
- 2017-11-29 JP JP2017228495A patent/JP2018058873A/ja active Pending
-
2018
- 2018-03-02 AU AU2018201522A patent/AU2018201522A1/en not_active Abandoned
-
2019
- 2019-10-11 AU AU2019246921A patent/AU2019246921B2/en active Active
-
2020
- 2020-01-27 JP JP2020010476A patent/JP2020090518A/ja active Pending
-
2024
- 2024-04-04 US US18/627,081 patent/US20250066336A1/en active Pending
-
2025
- 2025-07-18 US US19/274,318 patent/US20250346584A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250346584A1 (en) | 2025-11-13 |
| JP6254163B2 (ja) | 2017-12-27 |
| US20250066336A1 (en) | 2025-02-27 |
| JP2015531764A (ja) | 2015-11-05 |
| ES2750640T3 (es) | 2020-03-26 |
| EP2884978B1 (en) | 2019-07-17 |
| WO2014028829A1 (en) | 2014-02-20 |
| US20150210673A1 (en) | 2015-07-30 |
| JP2020090518A (ja) | 2020-06-11 |
| US9682966B2 (en) | 2017-06-20 |
| AU2013302497A1 (en) | 2015-03-05 |
| EP2884978A4 (en) | 2016-01-13 |
| EP2884978A1 (en) | 2015-06-24 |
| AU2018201522A1 (en) | 2018-03-22 |
| AU2019246921A1 (en) | 2019-10-31 |
| JP2018058873A (ja) | 2018-04-12 |
| DK2884978T3 (da) | 2019-09-30 |
| EP3584246A1 (en) | 2019-12-25 |
| US20180099954A1 (en) | 2018-04-12 |
| AU2019246921B2 (en) | 2021-04-01 |
| US10118915B2 (en) | 2018-11-06 |
| CA2882132A1 (en) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019246921B2 (en) | Novel kappa opioid ligands | |
| ES2672732T3 (es) | Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina | |
| US9586928B2 (en) | Modulators of the nuclear hormone receptor ROR | |
| ES2672624T3 (es) | Inhibidores de mecanismo doble para el tratamiento de enfermedades | |
| WO2012009258A2 (en) | Peptidomimetic galanin receptor modulators | |
| US20170327512A1 (en) | Modulators of vasopressin receptors with therapeutic potential | |
| US9656994B2 (en) | Substituted benzimidazoles as nociceptin receptor modulators | |
| US9051265B2 (en) | N-benzylindole modulators of PPARG | |
| US10584116B2 (en) | Heterocyclic sulfonamide derivative and medicine containing same | |
| US9850276B2 (en) | Bidentate-binding modulators of LRRK2 and JNK kinases | |
| ES2293253T3 (es) | Derivador de n-feniletil)suklfamida como antagonistas de la integrina alfa4. | |
| WO2014116684A1 (en) | Non-peptidic neuropeptide y receptor modulators | |
| WO2014018859A1 (en) | Klf5 modulators | |
| JP6118892B2 (ja) | デュオカルマイシン類縁体の環式プロドラッグ | |
| WO2024235218A1 (zh) | Hdac1/2选择性抑制剂及其用途 | |
| ES2671398T3 (es) | Derivados de ciclopentilamina 3-sustituida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180710 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250625 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250625 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260623 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260624 |